Navigation Links
NCCN Updates Supportive Care Guidelines for VTE
Date:5/20/2009

NCCN recently updated the NCCN Guidelines for Venous Thromboembolic Disease, which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE), and is a common condition in people with cancer. Noted updates include the expanded use of graduated compression stockings in prophylaxis and treatment, and a strengthened recommendation for VTE prophylaxis in general.

FORT WASHINGTON, Pa., May 20 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) announces new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Venous Thromboembolic Disease. These changes reflect leading developments in the treatment of patients with cancer and represent the standard of clinical policy in oncology in both community and academic settings.

The NCCN Guidelines for Venous Thromboembolic Disease are one of the NCCN Guidelines for Supportive Care. Venous Thromboembolism (VTE), commonly known as "economy class syndrome," includes both deep venous Thrombosis (DVT) and pulmonary embolism (PE), and is a common and life-threatening condition in people with cancer. The incidence of cancer-related VTE is further increased by additional risk factors such as thrombophilic mutations, prolonged immobilization, surgical procedures, and chemotherapeutic regimens.

Noteworthy updates to the NCCN Guidelines for Venous Thromboembolic Disease include a recommendation for the use of graduated compression stockings as inpatient prophylaxis, as well as a treatment for patients with central DVT who are tolerating anticoagulation treatment.

For patients in high-risk settings (e.g. those receiving highly thrombotic antiangiogenic therapy), the NCCN Guidelines strengthened the recommendation for VTE prophylaxis from 'consider' to 'recommend'. For patients with active cancer or persistent risk factors in the chronic VTE setting, the updated NCCN Guidelines also strengthened the suggestion for indefinite anticoagulation therapy from 'consider' to 'recommend'.

NCCN Clinical Practice Guidelines in Oncology(TM) are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. The most recent version of this and all the NCCN Guidelines are available free of charge at NCCN.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center - Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit NCCN.org.


'/>"/>
SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Updates Prescription Guidelines for Blood Thinner
2. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
3. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
4. MedQuist Updates Status of Outstanding SEC Filings
5. Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Managements Internal Control Review Efforts and on Legal Proceedings
6. ADA Updates Environmental Recommendations for Handling Waste
7. West Pharmaceutical Services Updates Annual Guidance
8. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
9. WallSt.net Updates Investment Community Through All-New Interview With Ingen Technologies
10. WallSt.net Updates Investment Community Through All-New Interview With XTend Medical
11. WallSt.net (www.wallst.net) Updates the Investment Community Through All-New Interviews With XMDC, POSS and TYPE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... of Justice jointly issued a letter to withdraw previous guidance issued ... their gender identity. The guidance issued in May 2016 by the Obama Administration ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... company focused on the development and commercialization of ... pain, announced that it will release fourth quarter ... Thursday, March 2nd, 2017. AcelRx management will host ... Time (1:30 p.m. Pacific Time) on March 2 ...
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... of around 1.8% over the next decade to reach approximately $12.8 billion ... estimates and forecasts for all the given segments on global as well ...
Breaking Medicine Technology: